anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a vaccine, preferably for human use, for symptom relaxant or prevention of evoked IgE-mediated allergic reactions.  &lt;P&gt;SOLUTION: This vaccine contains a protein having the entire amino acid sequence of constant C&lt;SB&gt;H&lt;/SB&gt;2-C&lt;SB&gt;H&lt;/SB&gt;3 domains in the epsilon chain of an IgE molecule or a structurally stable unit of the amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent on the antigen specificity of the IgE molecule but can reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain extract which consists of water of seaweeds, an org. solvent or water and org. solvent liquid mixture and is used for food additives, medicaments and cosmetics requiring clarity. SOLUTION: The extraction solvent is water, ethanol, propylene glycol, 1,3-butanediol, glycerol and a liquid mixture consisting of a combination arbitrarily selected therefrom. The seaweeds are extracted by this solvent and is filtered by using &lt;=3 kinds of filter aids varying in average particle sizes. As a result, the seaweed extraction liquid which is clear in spite of a high concn. is obtd.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oral formulation for prevention and/or treatment of inflammation of mucosa of mammals&#39; digestive tract (especially, human belly) caused by infection of Helicobacter (especially, H. pylori).  &lt;P&gt;SOLUTION: This formulation comprises at least one of xanthophylls in an efficient amount for prevention and treatment. The most favorable xanthophyll is oil-soluble astaxanthin, and a natural astaxanthin esterified by fatty acid is favorable. This oral formulation sometimes further contains a hydrocarbon structure derived from the cell wall of a productive algae: Haematococcus. This formulation may contain a water-soluble antioxidant, e.g., ascorbic acid (vitamin C) in an efficient amount for prevention and/or treatment. This oral formulation is provided in a separate unit dosage or in a mixture with foods.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to experimental surgery, and can be used for correction of ischemic liver affection. For this purpose 2 hours before operation 5% mexicor solution in dose 10 mg/kg of weight is intravenously jet injected to experimental animal. After that one hour before operation actovegin in dose 10 mg/kg of weight is intravenously jet injected. During operation ischemia is created by temporal extracorporal portacaval shunting. In post-operation period each of preparations is introduced 1 time a day during 7 days. Interval between their introduction is 12 hours: mexicor is introduced at 8 o&#39;clock, actovegin - at 20 o&#39;clock. ^ EFFECT: method ensures reduction of reperfusion disorders, elongation of safe terms of liver exsanguination up to 30 minutes and prevention of massive hemorrhage in operations on this organ. ^ 3 dwg, 4 tbl, 3 ex
1. Technical result Creation of novel, more active and less toxic agents of this class.         2. Essence N,N-dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-yl- methyl)-1H-indol-3-yl)ethylamine is deleted. Indole derivatives of formula I are useful in prophylaxis of clinical states for which administration of &#34;5-HT1- like receptor agonist is recommended. Also described are method of preparation thereof, drug based on indole derivatives of formula I and method of preparing drug; EFFECT: improved properties of the drug and more efficient preparation method thereof 3. Field of Application Medicine, pharmacology.
Systems and methods for automatic health data processing are disclosed. One or more complaints are extracted from question and answer data of an automated patient interview. A parent-child symptom mapping is referenced to identify a respective parent symptom corresponding to each complaint. Based on the question and answer data, a presence or absence of evidence of the child symptoms associated with each identified parent symptom is determined. The child symptoms are categorized into a positive or negative category based on the determination. An object is generated that includes, for each of the complaints, a positive and negative list of any of the child symptoms included in the positive and negative category, respectively. The object is processed to generate a history of present illness (HPI) portion of a notation in a graphical format. The notation is stored in the patient&#39;s electronic health record, and a healthcare provider notification is transmitted.
PURPOSE:To obtain a mouth wash having inhibiting effect against the activity of hyaluronidase called as phlogogenic enzyme participating in inflammation and useful as a preventive and remedy for periodontal diseases by using extract and/or powder of a plant such as JIYU (root of Sanguisorba officinalis), EIJITSU (fruit of Rosa multiflora), black tea, green tea and camellia as active component. CONSTITUTION:The objective dentifrice contains extract and/or powder of one or more kinds of plants selected from JIYU, EIJITSU, black tea, green tea, camellia and KINMA (Peper betle). The active component is compounded with an abrasive, humectant, surfactant and preservative to obtain the dentifrice, etc. The amount of the active component in the mouthwash or dentifrice is preferably about &gt;=0.003% in terms of the original plant before extraction. JIYU is rhizome of burnet, a plant of family Rosaceae and EIJITSU is fruit of briar, a plant of family Rosaceae. KINMA is dried fruit cluster of Peper betle, a plant of family Piperaceae.
PROBLEM TO BE SOLVED: To obtain the subject intermediate by reaction of a cephalosporin derivative bearing methyl group on the 3-site with a specific compound to effect slight formation of byproduct Δ&lt;2&gt; -form on the cephem ring and also transform the methyl group on the 3-site to enaminomethyl group in high yield. SOLUTION: This intermediate of formula II is obtained by reaction of a compound of formula I (R&lt;1&gt; is an amino-protective group interposed with a carbon, sulfur or silicon atom, or an acyl; R&lt;2&gt; is a carboxyl-protective group) or a salt thereof with tris(dimethylamino)methane, wherein the amount of the tris(dimethylamino)methane to be used is pref. 2-3 equivalents per mol of the compound of formula. The above reaction is carried out using N- methylpyrrolidone as reaction solvent pref. at 10-20 wt. times based on the compound of formula I at 30-40 deg.C for 2-4 h. After hydrolyzing this compound of formula II, reaction of the reaction product with a disulfide compound in the presence of a phosphorus compound affords a raw material compound for antimicrobial agents.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to experimental surgery, and can be used to assess viability of a tissue engineering structure when closing a critical tracheal defect on an experimental animal model. Part of the tracheal wall of the experimental animal is excised between 2nd and 7th rings to form a critical tracheal wall defect of at least 2×4 mm, fixation of tissue engineering structure in defect area. At end of 3 months after fixation of the tissue engineering, the trachea is examined by the radial technique with construction of 3D-model for evaluation of a degree of constriction of the tracheal lumen. After 6 months post-mortal histological and immunohistochemical examination of the explanted tissue engineering structure is performed, diagnostic test results are used as following: percent of tracheal lumen narrowing in area of fixation of tissue engineering structure (F), at narrowing by 75 % and more are assigned 0 points, less than 75 % – 1 point; evaluation of epithelisation of internal surface of tissue engineering (S), with complete epithelisation – 1 point, with no epithelialization or partial epithelisation – 0 points; density of microvessels in a submucosal layer of a tissue engineering structure (B), with density of 0–25 mmis assigned 0 points, at 26–50 mm– 1 point, more than 50 mm– 2 points. Value Lcorresponding to the product of points is calculated by formula: L=F*S*B. In the case of the calculated value L&lt;1, the absence of viability of the tissue engineering structure is stated. At L≥1 is concluded on viability of tissue engineering structure.EFFECT: method provides obtaining reliable data on biological and physiological compatibility of tissue engineering structures based on matrices of different origin when the tracheal critical defect is closed on the model of the experimental animal by creating a reliable method for evaluating the viability of the tissue engineering structure when closing the critical airway defect, allowing to assess the biological and physiological compatibility of the tracheal implant.1 cl, 1 tbl, 2 ex, 5 dwg
The invention relates to a traditional Chinese medicinal formula for treatment of female irregular menstruation. The formula involves the following effective components by weight: 30g of hawthorn, 10g of safflower, and 200g of white spirit. The materials are soaked in the white spirit for 1 week. The obtained product can be taken orally twice every day, 45-30g each time, and the dosage is dependent on one&#39;s drinking capacity and does not cause drunkenness. With the efficacy of promoting blood circulation and removing stasis, the formula provided by the invention is mainly used for treatment of hypomenorrhea, purple black and agglomerate menstrual blood, abdominal pain, and reduced pain after discharge of blood clots, raw and cold food should be avoided and the female should be protected from cold. The traditional Chinese medicinal formula provided by the invention aims to treat female irregular menstruation.
The present invention may provide an apparatus for providing nicotine replacement therapy. The apparatus may include a processor. The processor may be configured to perform one or more actions. A user&#39;s abstinence procedure may be determined. A procedural intervention event based on a phase of the weaning procedure may be determined. A marker associated with the user may be determined. Modifications to the weaning program may be determined based on program intervention events.
This method is used in the pharmaceutical industry. It enables the derivation of concentrated and stable water suspensions, practically without any coagulate, with small mean size of the disperse particles (between 60 and 140 nanometres), narrow allocation of the same, as well as co-polymers with larger and regulated molecular mass, whose films are elastic, strong and may be used for medical pills coating. The method entails the continual adding of co-monomeric mixture to the surface substance - nonylphenol polyglycol ether, ethoxylated with 10 moles of ethylene oxide - for 4-6 hours, heated to 75-80 degrees C, and saturated with gaseous nitrogen, also containing the substance dodecylbenzol sulphonic c acid. The addition of the initiator - ammonium per sulphate - is carried out in 5-6 equal portions for 1-1.5 hours, with the inclusion of the monomeric mixture of 2-hydroxy ethyl methacrylate or diethylene glycol methacrylate, or diethylene glycol acrylate, or their mixture. The emulsion&#39;s co-polymerisation continues for about 10 hours and is considered complete after the residual monomers become less than 0.3%. The derived suspension may be used as a film-forming material.
A polypeptide-containing fat-mobilising substance, FMS-1A, and a polypeptide-containing anorexigenic substance, FMS-1B, are prepared from the urine of fasting or cold-acclimatised animals by addition, at an acidic pH, of an alkanol to give a precipitate, FMS-1, comprising the mixed crude substances, and extracting the precipitate firstly with water to give a solution of FMS-1A and then with dilute aqueous alkali to give a solution of FMS-1B.  The word &#34;anorexigenic&#34; is said to mean capable of causing loss of appetite.  The animals, preferably rats, or horses, goats, sheep, dogs, cows, or rabbits, may be fasted by first feeding on a high fat diet for several days, followed by removal of all food, with urine collection over the next 24 hours; the cold acclimatisation is effected by transfer of the animal kept at room temperature, to an environment at 5 DEG C. for 24 hours to 3 days, with concomitant urine collection.  FMS-1 is precipitated with, e.g. methanol, ethanol or propanol, from the urine acidified to pH 5.3 with benzoic, acetic, hydrochloric or sulphuric acid.  The alkali may be aqueous alkali-metal or alkaline earth metal hydroxide or carbonate.  The two substances FMS-1A and 1B may be purified and obtained in solid form by re-precipitation from the solutions with acidified alcohol, with subsequent dissolution of the precipitate in water or dilute alkali (whichever is appropriate), and lyophilisation.  Also described is the preparation of a similar polypeptide, &#34;Hypox FMS&#34;, by the same process but from urine from fasted hypophysectomised rats.  This substance has anorexigenic activity, but no effect upon fat metabolism.  FMS-1A and 1B are also said to cause hypoglycemia.  The invention includes injectable compositions of FMS-1A and 1B with an inert carrier.
PROBLEM TO BE SOLVED: To obviate the infiltration of the metal ions derived from electrodes into the body and to improve the safety by laminating a an inert electrode and a depolarizer which comes into contact with this electrode at the time of application and/or an electrolytic solvent contg. a pH control agent hardly soluble in this electrolytic solvent. SOLUTION: A packing part 1 is formed with a nonconductive synthetic resin to a cup shape and is provided with an edge part 1a on the outer side of an aperture. An electrode terminal part 2 is formed to a male hook shape inserted with a projecting part into the hole part bored in the ceiling part of the packing part 1. The inert electrode part 3 is disposed in the ceiling part of the packing part 1 and is covered by the base part of the electrode terminam part 2 in electrical connection thereto. A non-tacky adhesive gel 5 formed by dispersing, dissolving and gelatinizing &gt;=1 among the depolarizer, pH control agent and drugs in addition to a gelatinizing agent into the electrolyte solvent is packed into a packing chamber 4.  Further, the tacky adhesive layer 6 is laminated on the outer side of the edge part 1a of the packing part 1 and the aperture of the packing part 1 is coated with the liner part 7.
The present invention relates to a castration vaccine gene and a genetic engineering body for animals, which is used for producing castration genetic engineering subunit vaccines for livestock and poultry. The present invention belongs to the high-tech field of biotechnology. A method for producing the present invention comprises: artificially synthesizing LHRH gene segments used by livestock or poultry or used by both livestock and poultry, wherein NcoI and XhoI restriction enzyme sites are added to the 5&#39; end and the 3&#39; end of the LHRH gene segments; inserting a pET-32c plasmid to construct 4 kinds of pET-32c-LHRHn-N/X recombinant plasmids for expressing LHRH-Trx fusion protein; converting the recombinant plasmids into escherichia coli BL21(DE3). An expression product is soluble protein. The present invention with convenience of extraction and purification and effective castration can be used by both livestock and poultry and can be used for immunizing animals, such as chickens, pigs, sheep, rabbits, dogs, cats, etc. The construction of the recombinant plasmid pET-32cLHRH (L1, L2, L3, L4)-N/X is disclosed in the specification.
Extracts from aromatic plants entirely soluble in hot water are prepared by subjecting a plant, or part thereof, to the passage of aqueous saturated steam so that the volatile elements are distilled and the water-soluble non-volatile elements are extracted, concentrating the solution containing the water-soluble non-volatile elements and reuniting the concentrated part with the volatile elements.  The concentrate containing the water-soluble non-volatile elements may be mixed with a solid water-soluble physiologically inactive product such as lactose, saccharose, sorbose, sorbite or mannite before being reunited with the volatile elements so as to give either at once or after dessication a product in powdery, granular or paste form. The plants or parts thereof which may be treated include camomile flowers, clove flowers, elder flowers, anise seeds, coffee beans, cardamom flowers, caraway seeds, sweet-fennel seeds, vanilla pods or roots; garlic, calamus, galangale or ginger roots or rhizomes; bergamot, lemon, tangerine or orange peels; eucalyptus leaves, mat&lt;\&gt;ae, mint, tea, vervain, hyssop, marjoram, melitot and thyme.  The Specification as open to inspection under Sect. 91 comprises also the separation of the volatile elements by extraction with steam, condensation and separation, extraction with an organic solvent, enfleurage, distillation in a high vacuum and condensation by cold, or extraction with the help of a hot gas such as carbon dioxide and subsequent condensation by cold, separately forming the aqueous extract of the water-soluble non-volatile elements, concentrating the aqueous extract and uniting it with the volatile elements.  This subject-matter does not appear in the Specification as accepted.
NEW MATERIAL:A compound expressed by formula I (P is peptide residue having amino acid sequence of human calcitonin). USE:A remedy for hypercalcemia, Behcet&#39;s disease, etc. PREPARATION:For example, a microorganism, e.g. Escherichia coli, etc. is transformed with a plasmid containing a DNA containing a gene capable of coding a peptide expressed by formula II (n is a positive integer) and then cultivated in a culture medium to produce a fused protein containing the peptide expressed by formula II in the resultant culture. The above-mentioned fused protein is then treated with an enzyme, e.g. trypsin, etc., to afford the aimed human calcitonin precursor peptide expressed by formula I.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a health condition determination apparatus and a determination method for easily determining the condition of a subject&#39;s health, and to provide a display method.  &lt;P&gt;SOLUTION: The health condition determination apparatus includes: an acquiring means for acquiring physical data and blood components data of a subject, a data conversion formula, and data determination criteria; and a processing means for converting the physical data and the blood components data into relative values by using the data conversion formula to determine a risk of development into a lifestyle-related disease of the subject by using the data determination criteria. Preferably, the acquiring means further acquires a health condition assessment formula and health condition determination criteria. The processing means calculates health condition determination relative values by combining two or more of the physical data, the blood component data, and the relative values, and using the health condition assessment formula to determine a risk of development into the lifestyle-related disease of the subject by collating the health condition determination relative values with the health condition determination criteria. The acquiring means includes a storage means and a communication means.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention comprises a crystalline calcium salt of phenoxymethyl penicillin of the formula Pen2Ca, where Pen represents the phenoxy methyl penicillin ion C6H5OCH2C9H10N2O4S, said crystals containing 4 to 5 per cent water of crystallization.  The salt is prepared by adding calcium hydroxide or a calcium salt to a solution of phenoxymethylpenicillin or a salt thereof in the presence of sufficient water to provide the water necessary for crystallization. A solution of the free acid in, e.g., butyl or amyl acetate may be treated with an aqueous solution or suspension of calcium hydroxide or with a calcium salt such as the acetate in which the acid has a lower dissociation constant than that of phenoxymethyl penicillin acid.  In the case of water-soluble salts, e.g. sodium, potassium, ammonium or amine salts of phenoxymethyl penicillin and, e.g., calcium chloride, the reaction may be carried out in aqueous solution, if desired, in the presence of a buffer.  Examples are given of the preparation of the calcium salt of phenoxymethyl penicillin from the potassium, sodium, ammonium, diisopropylammonium, tertiary butyl ammonium, isopropylammonium, N,N - dimethyl - beta - hydroxy ammonium, 3 - methoxypropyl ammonium and cyclohexylammonium salts of phenoxymethylpenicillin and from the penicillin free acid. Calcium phenoxymethyl penicillin may be used injected to form a &#34;depot&#34; penicillin or may be administered orally (see Group VI). Reference is made in Provisional Specification to Specification 643,514.ALSO:Medicines for parenteral or oral administration comprise a crystalline calcium salt of phenoxymethyl penicillin containing 4 to 5 per cent water of crystallization (see Group IV (b)) and having a solubility in water at 20 DEG  C. of 1.1 per cent and a pharmaceutical carrier or diluent.  The stability of injections comprising aqueous suspensions of the calcium penicillin is increased by the addition of calcium ions, e.g. as calcium chloride.  The injections may also contain (a) surface active suspending agents such as lecithin, cetyl pyridinium chloride and &#34;Tweens&#34; (Registered Trade Mark), and (b) viscosity improvers such as carboxymethyl cellulose, polyvinyl pyrrolidone and gelatin.  In an example, calcium phenoxymethyl penicillin is coated with an ether solution of lecithin, the solvent removed and the coated salt suspended in an aqueous solution of carboxymethyl cellulose containing phenylmercuric acetate.  Oral preparations may be in the form of pills, tablets or capsules.  In an example, a tablet is prepared from calcium phenoxymethylpenicillin, starch, kaolin, gelatin and talc. Reference is made in the Provisional Specification to Specification 643,514, [Group IV(b)].
PURPOSE:To suppress the blooming of higher fatty acid from the titled cosmetic containing higher fatty acid, and to prevent the defects in appearance, by compounding an oil-soluble polysaccharide fatty acid ester and an oil-soluble polyvinyl derivative to the cosmetic. CONSTITUTION:A pencil cosmetic containing a higher fatty acid such as stearic acid, behenic acid, etc. as solid oil component, is compounded with a compound selected from the quaternary ammonium salts of an oil-soluble polysaccharide fatty acid ester or an oil-soluble sulfate or phosphate of polysaccharide, and an oil-soluble polyvinyl derivative of formula I (X is R, OR, OCOR or group of formula II-V; R is alkyl; n is integer of &gt;=10). The amount of the compound is 0.01-5wt% based on the whole cosmetic and 0.02-30pts.wt. per 100pts.wt. of the higher fatty acid.